Argenx announces the uk mhra has granted early access to efgartigimod for generalized myasthenia gravis

Positive scientific opinion under early access to medicines scheme (eams) will make efgartigimod available to eligible generali z ed myasthenia gravis (gmg) patients in the uk prior to marketing authori z ation

ARGX Ratings Summary

ARGX Quant Ranking